ITP
LEGN icon

Iron Triangle Partners’s Legend Biotech LEGN Stock Holding History

Iron Triangle Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-380,000
Closed -$22.9M – 34
2023
Q4 		$22.9M Sell
380,000
-72,629
-16% -$4.6M 2.96% 17
2023
Q3 		$30.4M Buy
+452,629
New +$31.4M 4.44% 12
2023
Q2 		– Sell
-500,000
Closed -$24.1M – 28
2023
Q1 		$24.1M Buy
+500,000
New +$24.5M 3.48% 16
2022
Q3 		– Sell
-495,329
Closed -$27.2M – 32
2022
Q2 		$27.2M Buy
+495,329
New +$20.9M 3.53% 14

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Iron Triangle Partners's LEGN Position: Q1 2024 in Review

Iron Triangle Partners sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 380,000 shares — an estimated $22.9M sold.

Iron Triangle Partners first reported a position in LEGN in Q2 2022 and held it in 4 quarters. The position peaked at $30.4M in Q3 2023. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

  • Iron Triangle Partners reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
  • Iron Triangle Partners sold 380,000 Legend Biotech shares in Q1 2024, an estimated $22.9M.
  • Iron Triangle Partners first reported a position in Legend Biotech in Q2 2022 and held it in 4 quarters.
  • Iron Triangle Partners's Legend Biotech position peaked at $30.4M in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on Iron Triangle Partners's 13F filing for Q1 2024, filed 15 May 2024.